Trials / Completed
CompletedNCT05136053
A Study Investigating Lu AG22515 in Healthy Adults
A Phase 1, 3-Part, Single Ascending Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Lu AG22515 (APB-A1) in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- All
- Age
- 19 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The main goal of this study is to learn more about the safety of a drug called Lu AG22515. During the trial, healthy adult participants will receive a single dose of Lu AG22515 or a placebo (normal saline solution).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lu AG22515 | sterile solution for infusion |
| DRUG | Placebo | sterile solution for infusion |
| DRUG | Immune System Activator | sterile powder for injection |
Timeline
- Start date
- 2022-03-18
- Primary completion
- 2023-08-05
- Completion
- 2023-08-05
- First posted
- 2021-11-26
- Last updated
- 2023-08-28
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05136053. Inclusion in this directory is not an endorsement.